Fig. 4.

Anti‐proliferation of human GIST cancer cell lines and patient‐derived primary cells after treating with nintedanib and imatinib within FGF‐2. (A) Effects of nintedanib, imatinib and sunitinib on proliferation of GIST‐T1 and GIST‐882 cell lines within 20 ng·mL⁻¹ FGF2 for 3 days using CellTiter‐Glo assay. Data are shown as mean ± SD (n = 3, independent experiments). (B) Effects of nintedanib and imatinib on the FGFR and KIT signalling pathways in GIST‐T1 and GIST‐882 cell lines within 20 ng·mL⁻¹ FGF2 for 4 h (immunoblotting; n = 3, independent experiments). (C) GIST‐T1 and GIST‐882 cell lines were treated with imatinib for 4 h to activate FGF/FGFR signalling pathway, after which imatinib was removed and the cells were treated with nintedanib for 4 h for immunoblotting analysis. This experiment was conducted once. (D) Effects of nintedanib and imatinib on the FGFR and KIT signalling pathways in three GIST patients within 20 ng·mL⁻¹ FGF2 for 4 h (immunoblotting).